lenalidomide,carfilzomib,daratumumab,lenalidomide
janssen,amgen
daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation allowed 70% of patients with high-risk, newly diagnosed multiple myeloma to complete a second autologous stem cell transplant. #mmsm #ims2022 
Oncology news and insights from leading researchers and cancer centers.